Table 2.
Effectiveness of subsequent chemotherapy
| Variables | All | PTX | PTX + Cmab | S1 | p value |
|---|---|---|---|---|---|
| Number of patients (%) | 51 | 32 (62.7) | 9 | 10 | |
| Best response (%) | |||||
| Complete response | 4 (7.84) | 4 (12.5) | 0 (0) | 0 (0) | |
| Partial response | 33 (64.7) | 21 (65.6) | 8 (88.9) | 4 (40.0) | |
| Stable disease | 7 (21.6) | 3 (9.4) | 1 (11.1) | 3 (30.0) | |
| Progressive disease | 7 (21.6) | 4 (12.5) | 0 (0) | 3 (30.0) | |
| ORR (%) | 71.2 | 78.1 | 88.9 | 40 | 0.03 |
| DCR (%) | 84.6 | 87.5 | 100 | 70 | 0.20 |
PTX, paclitaxel; Cmab, cetuximab; S1, tegafur–gimeracil–oteracil potassium; ORR, objective response rate; DCR, disease control rate